1,180
Participants
Start Date
August 2, 2020
Primary Completion Date
January 16, 2021
Study Completion Date
May 20, 2021
Bamlanivimab
Administered IV.
Placebo
Administered IV.
Etesevimab
Administered IV.
Care Access Research - Bronx, The Bronx
Donahoe Manor, Bedford
NIAID - National Institute of Allergy & Infectious Diseases, Bethesda
Burke Internal Medicine and Research, Burke
NIAD, Chapel Hill
NIAID, Decatur
NIAID, Miami
Unv of AL Sch of Med Div of Infectious Diseases, Birmingham
Care Access, Jackson
University of Mississippi Medical Center, Jackson
University of Louisville, Louisville
Univ of Cin College of Med, Cincinnati
Valley Medical Primary Care, Centerville
Family Medicine, Indianapolis
St. Paul IDA-CARe, Saint Paul
Belmont Village Lincoln Park, Lincoln Park
Children's Hospital & Medical Center, Omaha
Care Access Rch Lake Charles, Lake Charles
Allergy and Asthma Clin of NW Ark, Bentonville
OSU Med Intl Med Houston Ctr, Tulsa
Belmont Village, West Univ, Houston
University of Colorado-Anschultz Medical Campus, Aurora
Care Access Research, Phoenix
Care Access Research LLC, Huntington Beach
Alta Bates SMC, Oakland
Tulane University School of Medicine, New Orleans
Care Access, Boston
Collaborators (1)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
AbCellera Biologics Inc.
INDUSTRY
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Eli Lilly and Company
INDUSTRY